Pediatric Infectious Disease

Register      Login

VOLUME 6 , ISSUE 1 ( January-March, 2024 ) > List of Articles

Original Article

Immunogenicity of Two Fractional Inactivated Poliovirus Vaccine Doses vs Single Intramuscular Inactivated Poliovirus Vaccine Dose in Infants of Low- and Middle-income Countries: A Prospective Case-control Study

Kunal Kumar, Sangita Yadav, Raghvendra Singh, Archana Thakur

Keywords : Inactivated poliovirus vaccine, Mean antibody titers, Seroconversion, Seroprotection

Citation Information : Kumar K, Yadav S, Singh R, Thakur A. Immunogenicity of Two Fractional Inactivated Poliovirus Vaccine Doses vs Single Intramuscular Inactivated Poliovirus Vaccine Dose in Infants of Low- and Middle-income Countries: A Prospective Case-control Study. Pediatr Inf Dis 2024; 6 (1):14-18.

DOI: 10.5005/jp-journals-10081-1418

License: CC BY-NC 4.0

Published Online: 16-03-2024

Copyright Statement:  Copyright © 2024; The Author(s).


Aims and background: Despite the support of the Global Alliance for Vaccines and Immunization, developing countries still struggle to afford inactivated polio vaccine (IPV). This study was undertaken to evaluate and compare the serological status of infants being offered two doses of intradermal fractional inactivated polio vaccine (ID-f-IPV) vs a single full dose administered intramuscularly (IM-SD-IPV) in conjunction with routine bivalent oral poliovirus vaccine (bOPV). Materials and methods: This prospective cross-sectional study was conducted in an Indian tertiary care healthcare center. The study consisted of 80 participants, with 40 in each group. The study measured the levels of antibodies using human poliovirus (PV) antibody immunoglobulin G (IgG) enzyme-linked immunosorbent assay (ELISA) kits and identified seroprotection as the presence of antibody >1:8 dilution. Seroconversion was described as a fourfold rise in antibody titers after 4 weeks. Results: Pre- and postimmunization mean antibody titers (MAT) in pg/mL against types I, II, and III PVs in the ID group were 192.26 ± 49.5, 162.96 ± 34.1, 131.32 ± 38.4, and 1743.58 ± 391.6, 1272.10 ± 341.3, 1105.71 ± 331.1, respectively. However, in the IM group, they were 523.83 ± 102.5, 209.47 ± 57.3, 426.57 ± 61.7, 2101.32 ± 282.1, 1033.08 ± 226.1, and 1381.04 ± 308.3, respectively. Around 100% of participants in both groups were seroprotected at pre- and postimmunization levels. Seroconversion against types I, II, and III serotypes in the ID-f-IPV group was 100% each, while in the IM-SD-IPV group, it was 62.5, 87.5, and 55%, respectively. Conclusion: The seroconversion rates of f-IPV were superior to the full dose IPV and may be a cost-effective choice for low- and middle-income countries.

PDF Share
  1. Polio Eradication Strategy 2022–2026: Delivering on a promise. Geneva. World Health Organization; 2021: ISBN 978-92-4-003194-4.
  2. Platt LR, Estívariz CF, Sutter RW. Vaccine-associated paralytic poliomyelitis: a review of the epidemiology and estimation of the global burden. J Infect Dis 2014;210(Suppl 1):S380–S389. DOI: 10.1093/infdis/jiu184
  3. Garon J, Seib K, Orenstein WA, et al. Polio endgame: the global switch from tOPV to bOPV. Expert Rev Vaccin 2016;15(6):693–708. DOI: 10.1586/14760584.2016.1140041
  4. Haldar P, Agrawal P. India's preparedness for introduction of IPV and switch from tOPV to bOPV. Indian Pediatr 2016;53(Suppl 1):S44–S49. PMID: 27771639.
  5. Grassly NC. Immunogenicity and effectiveness of routine immunization with 1 or 2 doses of inactivated poliovirus vaccine: systematic review and meta-analysis. J Infect Dis 2014;210(Suppl 1):S439–S446. DOI: 10.1093/infdis/jit601
  6. Resik S, Tejeda A, Sutter RW, et al. Priming after a fractional dose of inactivated poliovirus vaccine. N Engl J Med 2013;368(5):416–424. DOI: 10.1056/NEJMoa1202541
  7. Resik S, Tejeda A, Lago PM, et al. Randomized controlled clinical trial of fractional doses of inactivated poliovirus vaccine administered intradermally by needle-free device in Cuba. J Infect Dis 2010;201(9):1344–1352. DOI: 10.1086/651611
  8. Mohammed AJ, AlAwaidy S, Bawikar S, et al. Fractional doses of inactivated poliovirus vaccine in Oman. N Engl J Med 2010;362(25):2351–2359. DOI: 10.1056/NEJMoa0909383
  9. Anand A, Zaman K, Estívariz CF, et al. Early priming with inactivated poliovirus vaccine (IPV) and intradermal fractional dose IPV administered by a microneedle device: a randomized controlled trial. Vaccine 2015;33(48):6816–6822. DOI: 10.1016/j.vaccine.2015.09.039
  10. Nirmal S, Cherian T, Samuel BU, et al. Immune response of infants to fractional doses of intradermally administered inactivated poliovirus vaccine. Vaccine 1998;16(9-10):928–931. DOI: 10.1016/s0264-410x(97)00293-4
  11. Schnyder JL, De Pijper CA, Garcia Garrido HM, et al. Fractional dose of intradermal compared to intramuscular and subcutaneous vaccination - a systematic review and meta-analysis. Travel Med Infect Dis 2020;37:101868. DOI: 10.1016/j.tmaid.2020.101868
  12. Cadorna-Carlos J, Vidor E, Bonnet MC. Randomized controlled study of fractional doses of inactivated poliovirus vaccine administered intradermally with a needle in the Philippines. Int J Infect Dis 2012;16(2):e110–e116. DOI: 10.1016/j.ijid.2011.10.002
  13. Estívariz CF, Jafari H, Sutter RW, et al. Immunogenicity of supplemental doses of poliovirus vaccine for children aged 6-9 months in Moradabad, India: a community-based, randomised controlled trial. Lancet Infect Dis 2012;12(2):128–135. DOI: 10.1016/S1473-3099(11)70190-6
  14. Saleem AF, Mach O, Yousafzai MT, et al. Immunogenicity of different routine poliovirus vaccination schedules: a randomized, controlled trial in Karachi, Pakistan. J Infect Dis 2018;217(3):443–450. DOI: 10.1093/infdis/jix577
  15. Fadlyana E, Dhamayanti M, Tarigan R, et al. Immunogenicity and safety profile of a primary dose of bivalent oral polio vaccine given simultaneously with DTwP-Hb-Hib and inactivated poliovirus vaccine at the 4th visit in Indonesian infants. Vaccine 2020;38(8):1962–1967. DOI: 10.1016/j.vaccine.2020.01.007
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.